Renaissance Capital logo

ZYNE News

US IPO Weekly Recap: A bad week besides biotech

AIMT

Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of 12 IPOs ended their first day down or flat. The downward trend accelerated...read more

Pot patch company Zynerba prices IPO at $14, midpoint of the range

Zynerba Pharmaceuticals logo

Zynerba Pharmaceuticals, a preclinical biotech developing transdermal cannabinoid-based therapies, raised $42 million by offering 3 million shares at $14, the midpoint of the $13-$15 range. Perceptive Advisors, a biotech-focused hedge fund, has indicated...read more

Week ahead: 10 IPOs set to price during the week of August 3

Zynerba Pharmaceuticals logo

August 2015 kicks off with ten IPOs on the calendar for this week - more IPOs than all of August 2014 - after a slower than average July. Based on the number of broken and postponed IPOs last week, however, some of the ten will likely face heavy pushback on...read more

Will it trade high? Cannabis biotech Zynerba Pharmaceuticals sets terms for $42 million IPO

Zynerba Pharmaceuticals logo

Zynerba Pharmaceuticals, a preclinical biotech developing cannabinoid-based therapies for osteoarthritis and epilepsy, announced terms for its IPO on Thursday. The Devon, PA-based company plans to raise $42 million by offering 3.0 million shares at a price...read more